原发性肝癌患者介入治疗前后血清IGF-Ⅱ、CA19-9和AFP联检的临床意义

Clinical Significance of Combined Determination of the Changes of Serum IGF-Ⅱ,CA19-9 and AFP Levels After Intervention Therapy in Patients with Primary Hepatic Cancer

目的:探讨了原发性肝癌患者介入治疗前后血清IGF-Ⅱ、CA19-9和AFP水平的变化及临床意义。方法:应用放射免疫分析对35例原发性肝癌患者进行了血清IGF-Ⅱ、CA19-9和AFP含量检测,并与30名正常健康人作比较。结果:介入治疗前血清IGF-Ⅱ、CA19-9和AFP含量非常显著地高于正常人组(P<0.01),介入治疗后一个月皆已接近正常。介入治疗6个月再测,未复发者仍然属正常水平,而复发者又恢复至介入前水平。结论:测定原发性肝癌患者血清中IGF-Ⅱ、CA19-9和AFP水平的变化对患者的治疗和预后均具有重要的临床价值。

Objective To investigate the clinical significance of changes of serum IGF - Ⅱ , CA19 - 9 and AFP levels after intervention therapy in patients with primary hepatic cancer. Mothods Serum levels of IGF - Ⅱ , CA19 -9 and AFP （with RIA） were repeatedly determined in 35 patients with primary hepatic cancer before intervention therapy, 1 month after intervention therapy and 6 months after intervention therapy as wen as in 30 controls. Rosults Before intervention therapy, serum levels of IGF - Ⅱ , CA19 - 9 and AFP in the patients were significantly higher than those in the controls （P〈0.01）. One month after intervention therapy, all the serum levels were approaching normal. Six months later ,the levels in the patients without reetLrrence remained normal. However, the levels in the 6 patients with recurrence returued to those before intervention therapy again. Conclusion Changes of serum IGF - Ⅱ, CA19 - 9 and AFP levels are closely related to the tumor burden and may reflect the presence of recurrence .